Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 881–888 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
BeOne Medicines Ltd. Pamiparib (BGB-290) Maintenance Therapy Ovarian Cancer Phase 3 Oral Oncology
BeOne Medicines Ltd. Tislelizumab - (RATIONALE 303) Non-small cell lung cancer (NSCLC) Phase 3 Intravenous Oncology
BeOne Medicines Ltd. Tislelizumab Squamous non-small cell lung cancer (NSCLC) Phase 3 Intravenous Oncology
BeOne Medicines Ltd. Tislelizumab - (RATIONALE 309) Nasopharyngeal cancer (RM-NPC) Phase 3 Intravenous Oncology
BeOne Medicines Ltd. Tislelizumab and chemotherapy - (RATIONALE 304) Non-squamous non-small cell lung cancer (NSCLC) Phase 3 Intravenous Oncology
BeOne Medicines Ltd. Tislelizumab and chemoradiotherapy Esophageal squamous cell carcinoma (ESCC) Phase 3 Trial Completed Intravenous Oncology
BeOne Medicines Ltd. Sonrotoclax (sonro) in combination with zanubrutinib (zanu) Chronic lymphocytic leukemia/small lymphocytic leukemia, relapsed/refractory (R/R) mantle cell lymphoma (MCL) Phase 3 Trial Planned Oral Oncology
BeOne Medicines Ltd. Tislelizumab plus platinum-based doublet chemotherapy - (RATIONALE-315) Stage II-IIIA non-small cell lung cancer (NSCLC) Phase 3 Intravenous Oncology